The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol.

Novartis’ QMF149 met primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma.

The Indian government banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.